Kinins and Neuro-osteogenic Factors

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 1025-1057

  Lerner, Ulf H ^a   Persson, Emma ^a   Lundberg, Pernilpla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72249106068     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00063-X     Document Type: Chapter

References (288)

1. M. Ahmed, G.R. Srinivasan, E. Theodorsson, A. Bjurholm and A. Kreicbergs (1994) Extraction and quantitation of neuropeptides in bone by radioimmunoassay. Regul. Pept. 51 179-188.
2. A. Akopian, A. Demulder, F. Quriaghli, F. Corazza, P. Fondu and P. Bergmann (2000) Effect of CGRP on human osteoclast-like cell formation: A possible connection with the bone loss in neurological disorders? Peptides 21 559-564.
3. A.S.M.T. Alam, B.S. Moonga, P.J.R. Bevis, C.L.H. Huang and M. Zaidi (1991) Selective antagonism of calcitonin-induced osteoclastic quiescence (Q effect) by human calcitonin gene-related peptide-(Val8Phe37). Biochem. Biophys. Res. Commun. 179 134-139.
4. A.S.M.T. Alam, C.M.R. Bax, V.S. Shankar, B.E. Bax, P.J.R. Bevis, C.L.H. Huang, B.S. Moonga, M. Pazianas and M. Zaidi (1992) Further studies on the mode of action of calcitonin on isolated rat osteoclasts: Pharmacological evidence for a second site mediating intracellular Ca21 mobilization and cell retraction. J. Endocrinol. 136 7-15.
5. A.S. Alam, B.S. Moonga, P.J. Bevis, C.L. Huang and M. Zaidi (1992) Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp. Physiol. 78 183-196.
6. S.J. Allison, P. Baldock, A. Sainsbury, R. Enriquez, N.J. Lee, E.J. Lin, M. Klugmann, M. During, J.A. Eisman, M. Li, L.C. Pan, H. Herzog and E.M. Gardiner (2006) Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J. Biol. Chem. 33 23436-23444.
7. S.J. Allison, P.A. Baldock and H. Herzog (2007) The control of bone remodeling by neuropeptide Y receptors. Peptides 28 320-325.
8. S. Amano, M. Arai, S. Goto and A. Togari (2007) Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochem. Biophys. Acta 6 966-973.
9. A. Arimura (1991) Pituitary adenylate cyclase activating polypeptide (PACAP): Discovery and current status of research. Regul. Pept. 37 287-303.
10. A. Arimura (1992) Receptors for pituitary adenylate cyclase-activating polypeptide comparison with vasoactive intestinal peptide receptors. Trends Endocrinol. Metab. 3 288-294.
11. A. Arimura (1998) Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 48 301-331.
12. A. Arimura and S. Shioda (1995) Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: Neuroendocrine and endocrine interaction. Front. Neuroendocrinol. 16 53-58.
13. K. Asaumi, T. Nakanishi, H. Asahara, H. Inoue and M. Takigawa (2000) Expression of neurotrophins and their receptors (TRK) during fracture healing. Bone 26 625-633.
14. B. Averbeck, I. Izydorczyk and M. Kress (2000) Inflammatory mediators release calcitonin gene-related peptide from dorsal root ganglion neurons of the rat. Neuroscience 98 135-140.
15. H. Azuma, J. Kido, D. Ikedo, M. Kataoka and T. Nagata (2004) Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from Porphyromonas gingivalis. J. Periodontol. 75 974-981.
16. P.A. Baldock, A. Sainsbury, M. Couzens, R.F. Enriquez, G.P. Thomas, E.M. Gardiner and H. Herzog (2002) Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109 915-921.
17. P.A. Baldock, A. Sainsbury, S. Allison, E.J. Lin, M. Couzens, D. Boey, R. Enriquez, M. During, H. Herzog and E.M. Gardiner (2005) Hypothalamic control of bone formation: Distinct actions of leptin and Y2 receptor pathways. J. Bone Miner. Res. 20 1851-1857.
18. P.A. Baldock, S.A. Allison, M.M. McDonald, A. Sainsbury, R.F. Enriquez, D.G. Little, J.A. Eisman, E.M. Gardiner and H. Herzog (2006) Hypothalamic regulation of cortical bone mass: Opposing activity of Y2 receptor and leptin pathways. J. Bone Miner. Res. 21 1600-1607.
19. P.A. Baldock, S.A. Allison, P. Lundberg, N.J. Lee, K. Slack, E.J. Lin, R.F. Enriquez, M.M. McDonald, L. Zhang, M.J. During, D.G. Little, J.A. Eisman, E.M. Gardiner, E. Yulyaninguih, S. Lin, A. Sainsbury and H. Herzog (2007) Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J. Biol. Chem. 26 19092-19102.
20. R. Ballica, K. Valentijn, A. Khachatryan, S. Guerder, S. Kapadia, C. Gundberg, J. Gilligan, R.A. Flavell and A. Vignery (1999) Targeted expression of calcitonin gene-related peptide to osteoblasts increases bone density in mice. J. Bone Miner. Res. 14 1067-1074.
21. R. Battaglino, J. Fu, U. Spate, U. Ersoy, M. Joe, L. Sedaghat and P. Stashenko (2004) Serotonin regulates osteoclast differentiation through its transporter. J. Bone Miner. Res. 19 1420-1431.
22. R. Battaglino, M. Vokes, U. Schulze-Spate, A. Sharma, D. Graves, T. Kohler, R. Muller, S. Yoganathan and P. Stashenko (2007) Fluoxetine treatment increases trabecular bone formation in mice. J. Cell Biochem. 100 1387-1394.
23. C. Becskei, T. Riediger, D. Zünd, P. Wookey and T.A. Lutz (2004) Immunohistochemical mapping of calcitonin receptors in the adult brain. Brain Research 1030 221-233.
24. P. Bergmann, A. Heilporn, A. Schoutens, J. Paternot and A. Tricot (1977–1978) Longitudinal study of calcium and bone metabolism in paraplegic patients. Paraplegia 15 147-159.
25. P.S. Bhangu, P.G. Genever, G.J. Spencer, T.S. Grewal and T.M. Skerry (2000) Mechanisms for regulated uptake and release of glutamate by osteoblasts. J. Bone Miner. Res. 15(Suppl. 1), SU190.
26. F. Biering-Sörensen, H. Bohr and O. Schaadt (1988) Bone mineral content of the lumbar spine and lower extremities years after spinal cord lesion. Paraplegia 26 293-301.
27. F. Biering-Sörensen, H. Bohr and O. Schaadt (1990) Longitudinal study of bone mineral content in the lumbar spine, the forearm, and the lower extremities after spinal cord injury. Eur. J. Clin. Invest. 20 330-335.
28. Bjurholm, A. (1989). “Neuroendocrine Peptides in Bone.” Thesis, Universities of Stockholm and Umeå, Sweden.
29. A. Bjurholm, A. Kreicbergs and M. Schultzberg (1989) Fixation and demineralization of bone tissue for immunohistochemical staining of neuropeptides. Calcif. Tissue Int. 45 227-231.
30. A. Bjurholm, A. Kreicbergs, L. Terenius, M. Goldstein and M. Schultzberg (1988) Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J. Auton. Nerv. Syst. 25 119-125.
31. A. Bjurholm, A. Kreicbergs, E. Brodin and M. Schultzberg (1988) Substance P- and CGRP-immunoreactive nerves in bone. Peptides 9 165-171.
32. A. Bjurholm, A. Kreicbergs, M. Schultzberg and U.H. Lerner (1988) Parathyroid hormone and noradrenaline-induced enhancement of cyclic AMP in a cloned osteogenic osteosarcoma cell line (UMR 106–01) is inhibited by neuropeptide Y. Acta Physiol. Scand. 134 451-452.
33. A. Bjurholm, A. Kreicbergs, M. Schultzberg and U.H. Lerner (1992) Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 7 1011-1019.
34. M. Bliziotes, A. Eshleman, L. Vessely, X. Zhang and K. Wiren (2000) Expression of the serotonin transporter and serotonin potentiation of the PTH-induced cAMP response in osteoblastic cells. J. Bone Miner. Res. 15(Suppl. 1), SU213.
35. M. Bliziotes, S. McLoughlin, M. Gunnes, F. Fumagalli, S.R. Jones and M.G. Caron (2000) Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone 26 15-19.
36. M. Bliziotes, A.J. Eshleman, X.W. Zhang and K.M. Wiren (2001) Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone 29 477-486.
37. M. Bliziotes, A. Eshleman, B. Burt-Pichat, X.W. Zhang, J. Hashimoto, K. Wiren and C. Chenu (2006) Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 39 1313-1321.
38. A.G. Blomqvist and H. amd Herzog (2004) Y-receptor subtypes – how many more? Trends Neurosci. 7 294-298.
39. M. Bonyadi, S.D. Waldman, D. Liu, J.E. Aubin, M.D. Grynpas and W.L. Stanford (2003) Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc. Natl. Acad. Sci. U. S. A. 100 5840-5845.
40. A.B. Brechter and U.H. Lerner (2002) Characterization of bradykinin receptors in a human osteoblastic cell line. Regul. Peptides 103 39-51.
41. A.B. Brechter and U.H. Lerner (2007) Bradykinin potentiates cytokine induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclo-oxygenase-2 resulting in increased RANKL expression. Arthr. Rheum. 56 910-923.
42. A.B. Brechter, E. Persson, I. Lundgren and U.H. Lerner (2008) Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factro-α. Effects dependent on activation of NF- κB and MAP kinases. Bone 43 72-83.
43. N. Bühlmann, K. Leuthäuser, R. Muff, J.A. Fischer and W. Born (1999) A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 140 2883-2890.
44. Y. Cai, X. Xin, G.J. Shim, Y. Mokuno, H. Uehara, T. Yamada, T. Agui and K. Matsumo (1997) Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukine-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived cells. Endocrinology 138 2515-2520.
45. T. Cao, E. Pinter, S. Al-Rashed, J.R. Hoult and S.D. Brain (2000) Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: An in vivo study using neurokinin-1 receptor knockout mice. J. Immunol. 164 5424-5429.
46. C. Cayla, M. Todiras, R. Iliescu, V.V. Saul, V. Gross, B. Pilz, G. Chai, V.F. Merino, J.B. Pesquero, O.C. Baltau and M. Bader (2007) Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J. 21 1689-1698.
47. M.M. Cerinic, Y. Konttinen, S. Generini and M. Cutolo (1998) Neuropeptides and steroid hormones in arthritis. Curr. Opin. Rheumatol. 10 220-235.
48. C.L. Chang, J. Roh and S.Y.T. Hsu (2004) Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: A comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides 25 1633-1642.
49. C. Chenu, C.M. Serre, C. Raynal, B. Burt-Pichat and P.D. Delmas (1998) Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 22 295-299.
50. C. Chenu (2002) Glutamatergic innervation of bone. J. Microsc. Res. Tech. 15 70-76.
51. J. Christophe (1993) Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim. Biophys. Acta 1154 183-199.
52. D.S. Cissel, M. Murty, D.L. Whipkey, J.D. Blaha, G.M. Graeber and P.E. Keeting (1996) Estrogen pretreatment increases arachidonic acid release by bradykinin stimulated normal human osteoblast-like cells. J. Cell Biochem. 60 260-270.
53. J. Cornish, K.E. Callon, G.J.S. Cooper and I.R. Reid (1995) Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem. Biophys. Res. Commun. 207 133-139.
54. J. Cornish, K.E. Callon, D.H. Coy, N.Y. Jiang, L. Xiao, G.J.S. Cooper and I.R. Reis (1997) Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. Am. J. Physiol. 273 E1113-eE1120.
55. J. Cornish, K.E. Callon, A.R. King, G.J.S. Cooper and I.R. Reid (1998) Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am. J. Physiol. 275 E694-eE699.
56. J. Cornish, K.E. Callon, C.Q. Lin, C.L. Xiao, G.D. Gamble, G.J. Cooper and I.R. Reid (1999) Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J. Bone Miner. Res. 14 1302-1309.
57. J. Cornish, K.E. Callon, J.A. Gasser, U. Bava, E.M. Gardiner, D.H. Coy, G.J.S. Cooper and I.R. Reid (2000) Systemic administration of a novel octapeptide, amylin (1–8), increases bone volume in male mice. Am. J. Physiol. 279 E730-eE735.
58. J. Cornish, K.E. Callon, U. Bava, S.A. Kamona, G.J.S. Cooper and I.R. Reid (2001) Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29 162-168.
59. J.M. Cunha, F.Q. Cunha, S. Poole and S.H. Ferreira (2000) Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br. J. Pharmacol. 130 1418-1424.
60. E. Daci, N. Udagawa, T.J. Martin, R. Bouillon and G. Carmeliet (1999) The role of plasminogen system in bone resorption in vitro. J. Bone Miner. Res. 14 946-952.
61. E. Daci, A. Verstuyt, S.K. Moerman, R. Bouillon and G. Carmeliet (2000) Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J. Bone Miner. Res. 15 1510-1516.
62. R. Dacquin, R.A. Davey, C. Laplace, R. Levasseur, H.A. Morris, S.R. Goldring, S. Gebre-Medhin, D.L. Galson, J.D. Zajac and G. Karsenty (2004) Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J. Cell Biol. 164 509-514.
63. H.K. Datta, M. Zaidi, S.J. Wimalawansa, I.M.A. Ghatei, J.L. Beachman, S.R. Bloom and I. MacIntyre (1989) In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochem. Biophys. Res. Commun. 162 876-881.
64. M. Dauty, B. Perrouin Verbe, Y. Maugars, C. Dubois and J.F. Mathe (2000) Supralesional and sublesional bone mineral density in spinal cord-injured patients. Bone 27 305-309.
65. A.A. Decarlo, H. Grenett, J. Park, W. Balton, J. Cohen and P. Hardigan (2007) Association of gene polymorphisms for plasminogen activators with alveolar bone loss. J. Periodontal. Res. 42 305-310.
66. M.M.L. Deckers, M. Karperien, C. van der Bent, T. Yamashita, E. Papapoulos and C.W.G.M. Lowik (2000) Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141 1667-1674.
67. M. Delgado, C. Abad, C. Martinez, J. Leceta and R.P. Gomariz (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Med. 7 563-568.
68. M. Delgado, D. Pozo and D. Ganea (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56 249-290.
69. A. Demulder, M. Guns, A. Ismail, E. Wilmet, P. Fondu and P. Bergmann (1998) Increased osteoclast-like cells formation in long-term bone marrow cultures from patients with a spinal cord injury. Calcif. Tissue Int. 63 396-400.
70. Á. Dénes, Z. Boldogkio, G. Uhereczky, Á. Hornyák, M. Rusvai, M. Palkovits and K.J. Kovács (2005) Central autonomic control of the bone marrow: Multisynaptic tract tracing by recombinant pseudorabies virus. Neuroscience 134 947-963.
71. M. Devoto, K. Shimoya, J. Caminis, J. Ott, A. Tenenhouse, M.P. White, L. Sereda, S. Hall, E. Considine, C.J. Williams, G. Tromp, H. Kuivaniemi, L. Ala-Kokko, D.J. Prockop and L.D. Spotila (1998) First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur. J. Hum. Genet. 6 151-157.
72. K. Dohmen, N. Fukushima, T. Fujisaki, R. Iwakiri, Y. Yamano, M. Nagano, K. Wada, K. Kodama, K. Iwata, K. Hachimine and H. Ishibashi (1991) Giant metastatic VIPoma in the liver. Gastroenterol. Jpn. 26 530-535.
73. P. Ducy, M. Amling, S. Takeda, M. Priemel, A.F. Schilling, T. Beil, J. Shen, C. Vinson, J.M. Rueger and G. Karsenty (2000) Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100 197-207.
74. K. Edoff, J. Hellman, J. Persliden and C. Hildebrand (1997) The developmental skeletal growth in rat foot is reduced after denervation. Anat. Embryol. 195 531-538.
75. F. Elefteriou (2005) Neuronal signalling and the regulation of bone remodelling. Cell Mol. Life Sci. 62 2339-2349.
76. A.M. Elhassan, J.U. Lindgren, K. Hultenby, J. Bergström and A. Adem (1998) Methionine-enkephalin in bone and joint tissues. J. Bone Miner. Res. 13 88-95.
77. C. Emanueli, M. Bonaria Salis, T. Stacca, G. Pintus, R. Kirchmair, J.M. Isner, A. Pinna, L. Gaspa, D. Regoli, C. Cayla, J.B. Pesquero, M. Bader and P. Madeddu (2002) Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation 105 360-366.
78. A. Ericsson, M. Schalling, K.R. McIntyre, J.M. Lundberg, D. Larhammar, K. Seroogy, T. Hokfelt and H. Persson (1987) Detection of neuropeptide Y and its mRNA in megakaryocytes: Enhanced levels in certain autoimmune mice. Proc. Natl. Acad. Sci. U. S. A. 84 5585-5589.
79. L. Espinosa, C. Itzstein, H. Cheynel, P.D. Delmas and C. Chenu (1999) Active NMDA glutamate receptors are expressed by mammalian osteoclasts. J. Physiol. 518 47-53.
80. J. Fahrenkrug (2001) Gut/brain peptides in the genital tract: VIP and PACAP. Scand. J. Clin. Lab. Invest. Suppl. 234 35-39.
81. A.A. Fatokun, T.W. Stone and R.A. Smith (2006) Hydrogen peroxide-induced oxidative stress in MC3T3-E1 cells: The effects of glutamate and protection by purines. Bone 39 542-551.
82. C.E. Fiore, P. Pennisi, F. Ciffo, C. Scebba, A. Amico and S. DiFazzio (1999) Immobilization-dependent bone collagen breakdown appears to increase with time: Evidence for a lack of new bone equilibrium in response to reduced load during prolonged bed rest. Horm. Metab. Res. 31 31-36.
83. S.M. Foord and F.H. Marshall (1999) RAMPs: Accessory proteins for seven transmembrane domain receptors. TIPS 20 184-187.
84. I. Fristad, V. Vandevska-Radunovic, K. Fjeld, S.J. Wimalawansa and I. Hals Kvinnsland (2003) NK1, NK2, NK3, and CGRP1 receptors identified in rat oral soft tissues, and in bone and dental hard tissue cells. Cell Tissue Res. 311 383-391.
85. N. Fröhlander, Ö. Ljunggren and U.H. Lerner (1991) Haptoglobin synergistically potentiates bradykinin and thrombin induced prostaglandin biosynthesis in isolated osteoblasts. Biochem. Biophys. Res. Commun. 178 343-351.
86. A. Frost, K.B. Jonsson, P. Ridefelt, O. Nilsson, S. Ljunghall and Ö. Ljunggren (1999) Thrombin, but not bradykinin, stimulates proliferation in isolated human osteoblasts, via a mechanism not dependent on endogenous prostaglandin formation. Acta Orthop. Scand. 70 497-503.
87. F. Furlan, C. Galbiati, N.R. Jorgensen, J.E. Jensen, E. Mrak, A. Rubinacci, F. Talotta, P. Verde and F. Blasi (2007) Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J. Bone Miner. Res. 22 1387-1396.
88. D.E. Garland, C.A. Stewart, R.H. Adkins, S.S. Hu, C. Rosen, F.J. Liotta and D.A. Weinstein (1992) Osteoporosis after spinal cord injury. J. Orthopaed. Res. 10 371-378.
89. P.G. Genever and T.M. Skerry (2000) Regulated glutamate exocytosis is necessary for osteoblast differentiation and survival in vitro. J. Bone Miner. Res. 15(Suppl. 1), SU191.
90. H.P. Gerber, T.H. Vu, A.M. Ryan, J. Kowalski, Z. Werb and N. Ferrara (1999) VEGF couples hypertrophic cartilage remodeling, ossification, and angiogenesis during endochondral bone formation. Nature Med. 5 623-628.
91. T. Goto, T. Yamaza, M.A. Kido and T. Tanaka (1998) Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone. Cell Tissue Res. 293 87-93.
92. T. Goto, K. Nakao, K.K. Gunjigake, M.A. Kido, S. Kobayashi and T. Tanaka (2007) Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors. Neuropeptides 41 25-31.
93. I. Gozes and D.E. Brenneman (1993) Neuropeptides as growth and differentiation factors in general and VIP in particular. J. Mol. Neurosci. 4 1-9.
94. S. Granholm, P. Lundberg and U.H. Lerner (2008) Expression of calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J. Cell Biochem. 104 920-933.
95. S. Granholm, P. Lundberg and U.H. Lerner (2007) Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-κB and c-FMs. J. Endocrinol. 195 415-427.
96. E.M. Greenfield, M.C. Horowitz and S.A. Lavish (1996) Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cyclic AMP signal transduction. J. Biol. Chem. 271 10984-10989.
97. B.L. Grills and J.A. Schuijers (1998) Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone. Acta Orthop. Scand. 69 415-419.
98. B.L. Grills, J.A. Schuijers and A.R. Ward (1997) Topical application of nerve growth factors improves fracture healing in rats. J. Orthop. Res. 15 235-242.
99. D.A. Groneberg, K.F. Rabe and A. Fischer (2006) Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors. Eur. J. Pharmacol. 533 182-194.
100. Y. Gu and S.J. Publicover (2000) Expression of functional metabotropic glutamate receptors in primary cultured rat osteoblasts: Cross-talk with N-methyl-D-aspartate receptors. J. Biol. Chem. 275 34252-34259.
101. G.T. Gustafson and U.H. Lerner (1984) Bradykinin stimulates bone resorption and lysosomal-enzyme release in cultured mouse calvaria. Biochem. J. 219 329-332.
102. G.T. Gustafson, Ö. Ljunggren, P. Boonekamp and U. Lerner (1986) Stimulation of bone resorption in cultured mouse calvaria by Lys-bradykinin (kallidin), a potential mediator of bone resorption linking anaphylaxis processes to rarefying osteitis. Bone Miner. 1 267-277.
103. B.I. Gustafsson, L. Thommesen, A.K. Stunes, K. Tommeras, I. Westbroek, H.L. Waldum, K. Slordahl, M.V. Tamburstuen, J.E. Reseland and U. Syversen (2006) Serotonin and fluoxetine modulate bone cell function in vitro. J. Cell Biochem. 98 139-151.
104. T.J. Hall, B. Jagher, M. Schaeublin and I. Wiesenberg (1996) The analgesic drug buprenorphine inhibits osteoclastic bone resorption in vitro, but is proinflammatory in rat adjuvant arthritis. Inflamm. Res. 45 299-302.
105. R.C. Hamdy, S.W. Moore, V.A. Cancellaro and L.M. Harvill (1995) Long-term effects of strokes on bone mass. Am. J. Phys. Med. Rehabil. 74 351-356.
106. E.M. Haney, B.K. Chan, S.J. Diem, K.E. Ensrud, J.A. Cauley, E. Barrett-Connor, E. Orwoll and M.M. Bliziotes The Osteoporotic Fractures in Men Study Group (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use in older men. Arch. Intern. Med. 167 1246-1251.
107. A. Hattorl, M. Tsujimoto, K. Hayashi and M. Kohno (1996) Bone morphogenetic protein-2 is markedly synergistic with tumor necrosis factor in stimulating the production of nerve growth factor in fibroblasts. Biochem. Mol. Biol. Int. 38 1001-1095.
108. R.J. Henning and D.R. Sawmiller (2001) Vasoactive intestinal peptide: Cardiovascular effects. Cardiovasc. Res. 49 27-37.
109. E.L. Hill and R. Elde (1990) An improved method for preparing cryostat sections of undecalcified bone for multiple uses. J. Histochem. Cytochem. 38 443-448.
110. E.L. Hill and R. Elde (1991) Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 264 469-480.
111. E.L. Hill and R. Elde (1991) Effects of neonatal sympathectomy and capsaicin treatment on bone remodelling in rats. Neuroscience 44 747-755.
112. E. Hinoi, S. Fujimori and Y. Yoneda (2003) Modulation of cellular differentiation by N-methyl-D-aspartate receptors in osteoblasts. FASEB J. 17 1532-1534.
113. E. Hinoi, T. Takarada, K. Uno, M. Inoue, Y. Murafuji and Y. Yoneda (2007) Glutamate suppresses osteoclastogenesis through the cystine/glutamate antiporter. Am. J. Pathol. 170 1277-1290.
114. A.O. Hoff, P. Catala-Lehnen, P.M. Thomas, M. Priemel, J.M. Rueger, I. Nasonkin, A. Bradley, M.R. Hughes, N. Ordonez, G.J. Cote, M. Amling and R.F. Gagel (2002) Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J. Clin. Invest. 110 1849-1857.
115. E.L. Hohmann and A.H. Tashjian Jr. (1984) Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells. Endocrinology 114 1321-1327.
116. E.L. Hohmann, R.P. Elde, J.A. Rysavy, S. Einzig and R.L. Gebhard (1986) Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 232 868-871.
117. E.L. Hohmann, L. Levine and A.H. Tashjian Jr. (1983) Vasoactive intestinal peptide stimulates bone resorption via a cyclic adenosine 39, 59-monophosphate-dependent mechanism. Endocrinology 112 1233-1239.
118. T. Hökfelt, M. Scultzberg and J.M. Lundberg (1982) Distribution of vasoactive intestinal peptide in the central and peripheral nervous systems as revealed by immunocytochemistry. S.I. Said (Eds) Vacoactive Intestinal Peptide New York: Raven 185-192.
119. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam and R.G. Pertwee (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 161-202.
120. Hukkanen, M. (1994). “Neuropeptides in Central and Periphereal Nervous System: Their Role in the Pathophysiology of Painful Osteoarticular Inflammatory Disease and Trauma in Man and Animals.” Thesis, Royal Postgraduate Medical School, London, UK.
121. M. Hukkanen, Y.T. Konttinen, G. Rees, S. Santavirta, G. Terenghi and J.M. Polak (1992) Distribution of nerve endings and sensory neuropeptides in rat synovium, meniscus, and bone. Int. J. Tissue React. 14 1-10.
122. M. Hukkanen, Y.T. Konttinen, S. Santavirta, P. Paavolainen, X.H. Gu, G. Terenghi and J.M. Polak (1993) Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neuronal involvement in bone growth and remodelling. Neuroscience 54 969-979.
123. D.J. Hurrell (1937) The nerve supply of bone. J. Anat. 72 54-61.
124. K.J. Ibbotson, G.D. Roodman, L.M. McManus and G.R. Mundy (1984) Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline mononuclear cells. J. Cell Biol. 99 471-480.
125. A.I. Idris, R.J. van't Hof, I.R. Greig, S.A. Ridge, D. Baker, R.A. Ross and S.H. Ralston (2005) Regulation of bone mass, bone loss, and osteoclast activity by cannabinoid receptors. Nature Med. 11 774-779.
126. K. Ishizuka, K. Hirukawa, H. Nakamura and A. Togari (2005) Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci. Lett. 379 47-51.
127. N. Itoh, K. Obata, N. Yanaihara and I.I. Okamoto (1983) Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature 304 547-549.
128. C. Itzstein, L. Espinosa, P.D. Delmas and C. Chenu (2000) Specific antagonists of NMDA receptors prevent osteoclast sealing zone formation required for bone resorption. Biochem. Biophys. Res. Commun. 268 201-209.
129. E. Iwata, T. Nakanishi, N. Ogawa, K. Ohyama, T. Murakami and M. Takigawa (1996) Neurotrophin-3 increases the DNA-binding activities of several transcription factors in a mouse osteoblastic cell line. Biochim. Biophys. Acta. 1311 85-92.
130. F. Jehan, P. Naveilhan, I. Neveu, D. Harvie, E. Dicou, P. Brachet and D. Wion (1996) Regulation of NGF, BDNF and LNGFR gene expression in ROS 17/2.8 cells. Mol. Cell Endocrinol. 116 149-156.
131. L. Journot, C. Waeber, C. Pantaloni, F. Holsboer, P.H. Seeburg, J. Bockaert and D. Spengler (1995) Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. Biochem. Soc. Trans. 23 133-137.
132. Y. Juarranz, C. Abad, C. Martinez, A. Arranz, I. Gutierrez-Cañas, F. Rosignoli, R.P. Gomariz and J. Leceta (2005) Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 7 R1034-rR1045.
133. M. Karsak, M. Cohen-Solal, J. Freudenberg, A. Ostertag, C. Morieux, U. Kornak, J. Essig, E. Erxlebe, I. Bab, C. Kubisch, M.C. de Vernejoul M.–C. and A. Zimmer (2005) Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Gen. 14 3389-3396.
134. G. Karsenty (2006) Convergence between bone and energy homeostasis: Leptin regulation of bone mass. Cell Metab. 4 341-348.
135. T. Katafuchi and N. Minamino (2004) Structure and biological properties of three calcitonin receptor-stimulating peptides, novel members of the calcitonin gene-related peptide family. Peptides 25 2039-2045.
136. M. Kawamura and M.R. Urist (1988) Growth factors, mitogens, cytokines, and bone morphogenetic protein in induced chondrogenesis in tissue culture. Dev. Biol. 130 435-442.
137. E. Keshet, R.D. Polakiewicz, A. Itin, A. Omoy and H. Rosen (1989) Proenkephalin A is expressed in mesodermal lineages during organogenesis. EMBO J. 8 2917-2923.
138. P.J. King, G. Williams, H. Doods and P.S. Widdowson (2000) Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur. J. Pharmacol. 396 R1-rR3.
139. Y.T. Konttinen, S. Imai and A. Suda (1996) Neuropeptide and the puzzle of bone remodeling: State of the art. Acta Orthop. Scand. 67 632-639.
140. C.S. Kovacs, C.L. Chik, B. Li, E. Karpinski and A.K. Ho (1996) Pituitary adenylate cyclase-activating peptide stimulates cyclic AMP accumulation in UMR 106 osteoblast-like cells. J. Endocrinol. 149 287-295.
141. A. Kreicbergs and M. Ahmed (1997) Neuropeptides in bone. Curr. Opin Orthopedic. 8 71-79.
142. M. Laburthe and A. Couvineau (2002) Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regl. Pept. 108 165-173.
143. I. Laketic-Ljubojevic, L.J. Suva, F.J. Maathuis, D. Sanders and T.M. Skerry (1999) Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells. Bone 25 631-637.
144. L.M. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D.J. Pettibone and B.L. Zuraw (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57 27-77.
145. H.J. Leis, W. Hulla, R. Gruber, E. Huber, D. Zach, H. Gleispach and W. Windischhofer (1997) Phenotypic heterogeneity of osteoblast-like MC3T3-E1 cells: Changes of bradykinin-induced prostaglandin E2 production during osteoblast maturation. J. Bone Miner. Res. 12 541-551.
146. G. Leloup, C. Peeters-Joris, J-M. Delaisse, G. Opdenakker and G. Vaes (1991) Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone. J. Bone Miner. Res. 6 1081-1090.
147. U.H. Lerner (1991) Bradykinin synergistically potentiates interleukin-1 induced bone resorption and prostanoid biosynthesis in neonatal mouse calvarial bones. Biochem. Biophys. Res. Commun. 175 775-783.
148. U.H. Lerner (1994) Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 78 481-493.
149. U.H. Lerner (1997) The role of the kallikrein-kinin system in inflammation-induced bone metabolism. S.G. Farmer (Eds) The Kinin System New York: Academic Press 219-234.
150. U.H. Lerner (2000) The role of skeletal nerve fibers in bone metabolism. Endocrinologist 10 377-382.
151. U.H. Lerner (2004) New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Crit. Rev. Oral Biol. Med. 15 64-81.
152. U.H. Lerner (2006) Inflammation induced bone remodeling in periodontal disease and the influence of postmenopausal osteoporosis. J. Dent. Res. 85 596-607.
153. U.H. Lerner (2006) Bone remodeling in postmenopausal osteoporosis. J. Dent. Res. 85 584-595.
154. U.H. Lerner (2006) Deletions of genes encoding calcitonin/α-CGRP, amylin, and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone. J. Musculoskelet. Neuronal Interact. 6 87-95.
155. U.H. Lerner and N. Fröhlander (1992) Haptoglobin-stimulated bone resorption in neonatal mouse calvarial bones in vitro. Arthritis. Rheum. 35 587-591.
156. U.H. Lerner, I.L. Jones and G.T. Gustafson (1987) Bradykinin, a new potential mediator of inflammatory-induced bone resorption. Arthritis. Rheum. 30 530-540.
157. U.H. Lerner, M. Ransjö and O. Ljunggren (1989) Bradykinin stimulates production of prostaglandin E2 and prostacyclin in murine osteoblasts. Bone Miner. 5 139-154.
158. U.H. Lerner, Ö. Ljunggren, F. Dewhirst and D. Boraschi (1991) Comparison of human interleukin-1β and its 163–171 peptide in bone resorption and the immune response. Cytokine 3 141-148.
159. U.H. Lerner, P. Lundberg, M. Ransjö, P. Persson and R. Håkanson (1994) Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines. Calcif. Tissue Int. 54 284-289.
160. H.Y. Lin, T.L. Harris, M.S. Flannery, A. Aruffo, E.H. Kaji, A. Gorn, L.F. Kolakowski Jr., H.F. Lodish and S.R. Goldring (1991) Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254 1022-1024.
161. S. Lin, D. Boey, M. Couzens, N. Lee, A. Sainsbury and H. Herzog (2005) Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s). Neuropeptides 1 21-28.
162. Ö. Ljunggren and U.H. Lerner (1988) Stimulation of bone resorption by Met-Lys-bradykinin. J. Periodont. Res. 23 75-77.
163. Ö. Ljunggren and U.H. Lerner (1990) Evidence for BK1 bradykinin-receptor-mediated prostaglandin formation in osteoblasts and subsequent enhancement of bone resorption. Br. J. Pharmacol. 101 382-386.
164. Ö. Ljunggren, J. Rosenquist, M. Ransjö and U.H. Lerner (1990) Bradykinin stimulates prostaglandin E2 formation in isolated human osteoblast-like cells. Biosci. Rep. 10 121-126.
165. Ö. Ljunggren, R. Vavrek, J.M. Stewart and U.H. Lerner (1991) Bradykinin induced burst of prostaglandin formation in osteoblasts is mediated via B2 bradykinin receptors. J. Bone Miner. Res. 6 807-815.
166. Ö. Ljunggren, H. Johansson, S. Ljunghall, B.B. Fredholm and U.H. Lerner (1991) Bradykinin induces formation of inositol phosphates and causes an increase in cytoplasmic Ca2+ in the osteoblastic cell lineage MC3T3-E1. J. Bone Miner. Res. 6 443-452.
167. Ö. Ljunggren, B.B. Fredholm, C. Nordstedt, S. Ljunghall and U.H. Lerner (1993) Role of protein kinase C in bradykinin-induced prostaglandin formation in osteoblasts. Eur. J. Pharmacol. 244 111-117.
168. Lundberg, P. (2000). “The Neuropeptide VIP as a Regulator of Bone Cell Functions.” Thesis, Umeå University, Sweden.
169. P. Lundberg, I. Boström, H. Mukohyama, A. Bjurholm, K. Smans and U.H. Lerner (1999) Neuro-hormonal control of bone metabolism: Vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation in mineralised bone nodules. Regul. Pept. 85 47-58.
170. P. Lundberg, A. Lie, A. Bjurholm, P.P. Lehenkari, M.A. Horton, U.H. Lerner and M. Ransjö (2000) Vasoactive intestinal peptide binds to bone cells and regulates osteoclast activity. Bone 27 803-810.
171. P. Lundberg, I. Lundgren, H. Mukohyama, P.P. Lehenkari, M.A. Horton and U.H. Lerner (2001) VIP/PACAP receptor subtypes in mouse calvarial osteoblasts: Presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. Endocrinology 142 339-347.
172. P. Lundberg, S.J. Allison, N.J. Lee, P.A. Baldock, N. Brouard, S. Rost, R.F. Enriquez, A. Sainsbury, M. Lamghari, P. Simmons, J.A. Eisman, E.M. Gardiner and E.M. Herzog (2007) Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1-receptor expression. J. Biol. Chem. 26 19082-19091.
173. C. Lundstedt, T. Linjawi and T. Amin (1994) Liver VIPoma: Report of two cases and literature review. Abdom. Imaging 19 433-437.
174. I. MacIntyre (1989) Amylin-amide, bone conservation, and pancreatic b cells. Lancet ii 1026-1027.
175. E.J. Mackie, U. Trechsel and C. Bruns (1990) Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation. Development 110 1233-1239.
176. F. Marceau and D. Regoli (2004) Bradykinin receptor ligands: Therapeutic perspectives. Nat. Rev. Drug Discov. 3 845-852.
177. D.J. Mason, L.J. Suva, P.G. Genever, A.J. Patton, S. Steuckle, R.A. Hillam and T.M. Skerry (1997) Mechanically regulated expression of a neural glutamate transporter in bone: A role for excitatory amino acids as osteotropic agents? Bone 20 199-205.
178. D.J. Mason (2004) The role of glutamate transporters in bone cell signaling. J. Musculoskelet. Neuronal Interact. 4 128-131.
179. T. Matayoshi, T. Goto, E. Fukuhara, H. Takano, S. Kobayashi and T. Takayashi (2005) Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. Biochem. Biophys. Res. Commun. 327 756-764.
180. J. McCredie and W.G. McBride (1973) Some congenital abnormalities: Possible due to embryonic peripheral neuropathy. Clin. Radiol. 24 204-211.
181. B. Merle, C. Itzstein, P.D. Delmas and C. Chenu (2003) NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J. Cell Biochem. 90 424-436.
182. A. Miayata, A. Arimura, R.R. Dahl, N. Minamino, A. Uehara, L. Jiang, M.D. Culler and D.H. Coy (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164 567-574.
183. V.P. Michelangeli, D.M. Findlay, A. Fletcher and T.J. Martin (1986) Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106–01). Calcif. Tissue Int. 39 44-48.
184. V.P. Michelangeli, A.E. Fletcher, E.H. Allan, G.C. Nicholson and T.J. Martin (1989) Effects of calcitonin gene-related peptide on cyclic AMP formation in chicken, rat, and mouse bone cells. J. Bone Miner. Res. 4 269-272.
185. H.W. Minne, J. Pfeilschifter, S. Scharla, S. Mutschelknauss, A. Schwartz, B. Krempien and R. Ziegler (1984) Inflammation-mediated osteopenia in the rat, a new animal model for pathological loss of bone mass. Endocrinology 115 50-54.
186. Y. Miyamoto, Y. Habata, T. Ohtaki, Y. Masuda, K. Ogi, H. Onda and M. Fujino (1994) Cloning and expression of a complementary DNA encoding the bovine receptor for pituitary adenylate cyclase-activating polypeptide (PACAP). Biochim. Biophys. Acta. 1218 297-307.
187. M.E. Moreau, N. Garbacki, G. Molinaro, N.J. Brown, F. Marceau and A. Adam (2005) The kallikrein-kinin system: Current and future pharmacological targets. J. Pharmacol. Sci. 99 6-38.
188. T. Mori, T. Ogata, H. Okumura, T. Shibata, Y. Nakamura and K. Kataoka (1999) Substance P regulates the function of rabbit cultured osteoclasts; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochem. Biophys. Res. Commun. 262 418-422.
189. R. Morimoto, S. Uehara, S. Yatsushiro, N. Juge, Z. Hua, S. Senoh, N. Echigo, M. Hayashi, T. Mizoguchi, T. Ninomiya, N. Udagawa, H. Omote, A. Yamamoto, R.H. Edwards and Y. Moriyama (2006) Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J. 25 4175-4186.
190. R.J. Motley, D. Clements, W.D. Evans, E.O. Crawley, C. Evans, J. Rhodes and J.E. Compston (1993) A four-year longitudinal study of bone loss in patients with inflammatory bowel diesease. Bone Miner. 23 95-104.
191. R. Muff, N. Bühlmann, J.A. Fischer and W. Born (1999) An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 140 2924-2927.
192. H. Mukohyama, M. Ransjo, H. Taniguchi, T. Ohyama and U.H. Lerner (2000) The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem. Biophys. Res. Commun. 271 158-163.
193. V. Mutt and S.I. Said (1974) Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur. J. Biochem. 42 581-589.
194. M. Nakamura, S. Morimoto, Q. Yang, T. Hisamatsu, N. Hanai, Y. Nakamura, I. Mori and K. Kakudo (2005) Osteoclast-like cells express receptor activity modifying protein 2: Application of laser capture microdissection. J. Mol. Endocrinol. 34 257-261.
195. M. Nakamura, C. Sakanaka, Y. Aoki, H. Ogasawara, T. Tjuji, H. Kodama, T. Matsumoto, T. Shimizu and M. Noma (1995) Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing: Isolation, genomic structure, and functional expression of the receptors. J. Biol. Chem. 270 30102-30110.
196. T. Nakanishi, K. Ohyama, C. Aoki, A. Kudo, T. Hattori, K. Takahashi, S. Taniguchi and M. Takigawa (1994) Expression of trkC in a mouse osteoblastic cell line and response to neurotrophin-3. Biochem. Biophys. Res. Commun. 203 1268-1274.
197. T. Nakanishi, K. Ohyama, C. Aoki, A. Kudo, T. Hattori, K. Takahashi, S. Taniguchi and M. Takigawa (1994) Expression of nerve growth factor family neurotrophins in a mouse osteoblastic cell line and response to neurotrophin-3. Biochem. Biophys. Res. Commun. 198 891-897.
198. M. Notoya, R. Arai, T. Katafuchi, N. Minamino and H. Hagiwara (2007) A novel member of the calcitonin gene-related peptide family, calcitonin receptor-stimulating peptide, inhibits the formation and activity of osteoclasts. Eur. J. Pharmacol. 560 234-239.
199. O. Ofek, M. Karsak, N. Leclerc, M. Fogel, B. Frenkel, K. Wright, J. Tam, M. Attar-Namdar, V. Kram, E. Shohami, R. Mechoulam, A. Zimmer and I. Bab (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U. S. A. 103 696-701.
200. S.C. Offley, T.Z. Guo, T. Wei, J.D. Clark, H. Vogel, D.P. Lindsey, C.R. Jacobs, W. Yao, N.E. Lane and W.S. Kingery (2005) Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J. Bone Miner. Res. 20 257-267.
201. K. Ogi, Y. Miyamoto, Y. Masuda, Y. Habata, M. Hosoya, T. Ohtaki, Y. Masuo, H. Onda and M. Fujino (1993) Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor. Biochem. Biophys. Res. Commun. 196 1511-1521.
202. P. Palmqvist, P. Lundberg, E. Persson, A. Johansson, I. Lundgren, A. Lie, H.H. Conaway and U.H. Lerner (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J. Biol. Chem. 281 2414-2429.
203. M.S. Patel and F. Elefteriou (2007) The new field of neuroskeletal biology. Calcif. Tissue Int. 80 337-347.
204. P.E. Patterson-Buckendahl, R.E. Grindeland, D.C. Shakes, E.R. Morey-Holton and C.E. Cann (1988) Circulating osteocalcin in rats is inversely responsive to changes in corticosterone. Am. J. Physiol. 254 R828-r833.
205. A.J. Patton, P.G. Genever, M.A. Birch, L.J. Suva and T.M. Skerry (1998) Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone 22 645-649.
206. N.M. Peet, P.S. Grabowski, I. Laketic-Ljubojevic and T.M. Skerry (1999) The glutamate receptor antagonist MK 801 modulates bone resorption in vitro by a mechanism predominantly involving osteoclast differentiation. FASEB J. 13 2179-2185.
207. J.L. Pérez-Castrillón, J.M. Olmos, J.J. Gómez, A. Barrallo, J.A. Riancho, L. Perera, C. Valero, J.A. Amado and J. González-Macías (2000) Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology 72 187-194.
208. Persson, E. (2005). “The Neuropeptide VIP and the IL-6 Family of Cytokines in Bone.” Thesis, Umeå University, Sweden.
209. E. Persson, O.S. Voznesensky, Y.-F. Huang and U.H. Lerner (2005) Increased expression of interleukin-6 by vasoactive intestinal peptide is associated with regulation of CREB, AP-1 and C/EBP, but not NF-κB, in mouse calvarial osteoblasts. Bone 37 513-529.
210. E. Persson and U.H. Lerner (2005) The neuropeptide VIP potentiates IL-6 production induced by proinflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1. Biochem. Biophys. Res. Commun. 335 705-711.
211. J.B. Pesquero and M. Bader (2006) Genetically altered animal models in the kallikrein-kinin system. Biol. Chem. 387 119-126.
212. J. Pfeilschifter, R. Köditz, M. Pfohl and H. Schatz (2002) Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23 90-119.
213. P. Pietschmann, K.H. Farsoudi, O. Hoffmann, K. Klaushofer, H. Horander and M. Peterlik (1993) Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria. Bone 14 167-172.
214. M. Pondel (2000) Calcitonin and calcitonin receptors: Bone and beyond. Int J. Exp. Pathol. 81 405-422.
215. S. Rahman, R.A.D. Bunning, P.R.M. Dobson, D.B. Evans, K. Chapman, T.H. Jones, B.L. Brown and R.G.G. Russell (1992) Bradykinin stimulates the production of prostaglandin E2 and interleukin-6 in human osteoblast-like cells. Biochim. Biophys. Acta. 1135 97-102.
216. Ramnemark, A. (1999). “Osteoporosis and Fractures after Stroke.” Thesis, Umeå University, Sweden.
217. A. Ramnemark, L. Nyberg, R. Lorentzon, U. Englund and Y. Gustafson (1999) Progressive hemiosteoporosis on the paretic side and increased bone mineral density in the nonparetic arm the first year after severe stroke. Osteopor. Int. 9 269-275.
218. A. Ramnemark, L. Nyberg, R. Lorentzon, T. Olsson and Y. Gustafson (1999) Hemiosteoporosis after severe stroke, independent of changes in body composition and weight. Stroke 30 755-760.
219. S.R. Rawlings and M. Hezareh (1996) Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: Actions on the anterior pituitary gland. Endocr. Rev. 17 4-29.
220. M. Ransjö, A. Lie, H. Mukohyama, P. Lundberg and U.H. Lerner (2000) Microisolated mouse osteoclasts express VIP-1 and PACAP receptors. Biochem. Biophys. Res. Commun. 274 400-404.
221. S. Reissmann, F. Pineda, G. Vietinghoff, H. Werner, L. Gera, J.M. Stewart and I. Paegelow (2000) Structure relationships for bradykinin antagonists on the inhibition of cytokine release and the release of histamine. Peptides 21 527-533.
222. D.A. Ricupero, J.R. Romero, D.C. Rishikof and R.H. Goldstein (2000) Des-Arg10-kallidin engagement of the B1 receptor stimulates type 1 collagen synthesis via stabilization of connective tissue growth factor mRNA. J. Biol. Chem. 275 12475-12480.
223. J. Roh, C.L. Chang, A. Bhalla, C. Klein and S.Y.T. Hsu (2004) Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J. Biol. Chem. 279 7264-7274.
224. D.R. Romero, H.P. Bryer, B. Rucinski, J.A. Isserow, F.J. Buchinsky, M. Cvetkovic, C.C. Liu and S. Epstein (1995) Amylin increases bone volume but cannot ameliorate diabetic osteopenia. Calcif. Tissue Int. 56 54-61.
225. G.D. Roodman, K.J. Ibbotson, B.R. MacDonald, T.J. Kuehl and G.R. Mundy (1985) 1, 25-dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. Proc. Natl. Acad. Sci. U. S. A. 82 8213-8217.
226. B.A. Roos, J.A. Fischer, W. Pignaat, C.B. Alander and L.G. Raisz (1986) Evaluation of the in vivo and in vitro calcium-regulating actions of noncalcitonin peptides produced via calcitonin gene expression. Endocrinology 118 45-51.
227. H. Rosen, R.D. Polakiewicz, S. Benzakine and Z. Bar-Shavit (1991) Proenkephalin A in bone-derived cells. Proc. Natl. Acad. Sci. U. S. A. 88 3705-3709.
228. H. Rosen and Z. Bar-Shavit (1994) Dual role of osteoblastic proenkephalin derived peptides in skeletal tissues. J. Cell Biochem. 55 334-339.
229. H. Rosen, A. Krichevsky, R.D. Polakiewicz, S. Benzakine and Z. Bar-Shavit (1995) Developmental regulation of preoenkephalin gene expression in osteoblasts. Mol. Endocrinol. 9 1621-1631.
230. H. Rosen, A. Krichevsky and Z. Bar-Shavit (1998) The enkephalinergic osteoblast: Perspective. J. Bone Miner. Res. 13 1515-1520.
231. J.B. Rosenquist, A. Ohlin and U.H. Lerner (1996) Cytokine-induced inhibition of bone matrix proteins is not mediated by prostaglandins. Inflamm. Res. 45 457-463.
232. S.I. Said and V. Mutt (1969) Long-acting vasodilator peptide from lung tissue. Nature 224 699-700.
233. S.I. Said and V. Mutt (1970) Polypeptide with broad biological activity, isolation from small intestine. Science 169 1217-1218.
234. S.I. Said and R.N. Rosenberg (1976) Vasoactive intestinal polypeptide, abundant immunoreactivity in neural cell lines and normal nervous tissue. Science 192 907-908.
235. A.P.A. Sainsbury, C. Baldock, N. Schwarzer, R.F. Ueno, R. Enriquez, M. Couzens, A. Inni, H. Herzog and E.M. Gardiner (2003) Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol. Cell Biol. 23 5225-5233.
236. T. Sakai, Y. Okano, Y. Nozawa and N. Oka (1992) Different protein kinase C isoenzymes could modulate bradykinin-induced extracellular calcium-dependent and -independent increases in osteoblast-like MC3T3-E1 cells. Cell Calcium 13 329-340.
237. H.S. Sandhu, M.S. Herskovits and I.J. Singh (1987) Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat. Rec. 219 32-38.
238. K. Sato and H. Takayanagi (2006) Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr. Opin. Rheumatol. 18 419-426.
239. T. Schinke, S. Liese, M. Priemel, M. Haberland, A.F. Schilling, P. Catala-Lehnen, D. Blicharski, J.M. Rueger, R.F. Gagel, R.B. Emeson and M. Amling (2004) Decreased bone formation and osteopenia in mice lacking α-calcitonin gene-related peptide. J. Bone Miner. Res. 19 2049-2056.
240. C.A. Schuttleworth and K.D. Keef (1995) Roles of peptides in enteric neuromuscular transmission. Regul. Pept. 56 101-120.
241. C.M. Serre, D. Farlay, P.D. Delmas and C. Chenu (1999) Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 25 623-629.
242. P.M. Sexton (1992) Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol. Neurobiol. 5 251-273.
243. J.N. Sharma (2006) Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system. Arch. Med. Res. 37 299-306.
244. M.S. Sherman (1963) The nerves of bone. J. Bone Joint Surg. 45 522-528.
245. C. Shih and G.W. Bernard (1997) Calcitonin gene-related peptide enhances bone colony development in vitro. Clin. Orthop. 334 335-344.
246. C. Shih and G.W. Bernard (1997) Neurogenic substance P stimulates osteogenesis in vitro. Peptides 18 323-326.
247. T.M. Skerry (1999) Identification of novel signaling pathways during functional adaptation of the skeleton to mechanical loading: The role of glutamate as a paracrine signaling agent in the skeleton. J. Bone Miner. Res. 17 66-70.
248. S.J. Sohn (2005) Substance P upregulates osteoclastogenesis by activating nuclear factor kappa B in osteoclast precursors. Acta Otolaryngol. 125 130-133.
249. G.J. Spencer, C.J. McGrath and P.G. Genever (2007) Current perspectives on NMDA-type glutamate signaling in bone. Int. J. Biochem. Cell Biol. 39 1089-1104.
250. H.H. Strange-Vognsen, J. Arnbjerg and J. Hannibal (1997) Immunocytochemical demonstration of pituitary adenylate cyclase activating polypeptide (PACAP) in the porcine epiphyseal cartilage canals. Neuropeptides 31 137-141.
251. A. Susuki, J. Kontoyori, Y. Oiso and O. Kozawa (1994) Pituitary adenylate cyclase activating peptide induces cAMP production independently from vasoactive intestinal polypeptide in oestoblast-like cells. Cell Signal. 6 11-16.
252. M. Svoboda, M. Tastenoy, E. Ciccarelli, M. Stievenart and J. Christophe (1993) Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor. Biochem. Biophys. Res. Commun. 15 881-888.
253. A.M. Szczesniak, R.W. Gilbert, M. Mukhida and G.I. Anderson (2005) Mechanical loading modulates glutamate receptor subunit expression in bone. Bone 37 63-73.
254. Y. Takada, S. Aoe and M. Kumegawa (1996) Whey protein stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 223 445-449.
255. Y. Takada, N. Kobayashi, K. Kato, H. Matsuyama, M. Yahiro and S. Aoe (1997) Effect of whey protein on calcium and bone metabolism in ovariectomised rats. J. Nutr. Sci. Vitaminol. 43 199-210.
256. H. Takayanagi (2005) Mechanistic insights into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83 170-179.
257. H. Takayanagi (2007) Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nature Rev. 7 292-304.
258. Y. Takei, K. Inoue, M. Ogoshi, T. Kawahara, H. Bannai and S. Miyano (2004) Identification of novel adrenomedullin in mammals: A potent cardiovascular and renal regulator. FEBS Letters 556 54-58.
259. J. Tam, O. Ofek, E. Fride, C. Ledent, Y. Gabet, R. Muller, A. Zimmer, K. Mackie, R. Mechoulam, E. Shohami and I. Bab (2006) Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol. Pharmacol. 70 786-792.
260. T. Tamura, C. Miyaura, I. Owan and T. Suda (1992) Mechanism of action of amylin on bone. J. Cell Physiol. 153 6-14.
261. D. Thiebaud, T. Akatsu, T. Yamashita, T. Suda, T. Noda, R.E. Martin, A.E. Fletscher and T.J. Martin (1991) Structure-activity relationships in calcitonin gene-related peptide: Cyclic AMP response in a preosteoblast cell line (KS-4). J. Bone Miner. Res. 6 1137-1142.
262. C.W. Tiffany and R.M. Burch (1989) Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. FEBS Lett. 247 189-192.
263. J.R. Tippins, H.R. Morris, M. Panico, T. Etienne, P. Bevis, S. Girgis, I. MacIntyre, M. Azria and M. Attinger (1984) The myotropic and plasma calcium-modulating effects of calcitonin gene-related peptide (CGRP). Neuropeptides 4 425-434.
264. A. Togari (2002) Adrenergic regulation of bone metabolism: Possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc. Res. Tech. 58 77-84.
265. A. Togari, M. Arai and A. Kondo (2005) The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin. Ther. Targets 9 931-940.
266. A. Togari, M. Arai, S. Mizutani, Y. Koshihara and T. Nagatsu (1997) Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci. Lett. 19 125-128.
267. K. Uno, T. Takarada, E. Hinoi and Y. Yoneda (2007) Glutamate is a determinant of cellular proliferation through modulation of nucelar factor E2 p45-related factor-2 expression in osteoblastic MC3T3-E1 cells. J. Cell Physiol. Epub ahead of print.
268. B. Uzan, M.C. de Vernejoul and M. Cressent (2004) RAMPs and CRLR expressions in osteoblastic cells after dexamethasone treatment. Biochem. Biophys. Res. Commun. 321 802-808.
269. K. Valentijn, A.P. Gutow, N. Troiano, C. Gundberg, J.P. Gilligan and A. Vignery (1997) Effects of calcitonin gene-related peptide on bone turnover in ovariectomized rats. Bone 21 269-274.
270. P.M. Van Hagen, L.J. Hofland, A.M. Bokum, E.M. Lichtenauer-Kaligis, D.J. Kwekkeboom, D. Ferone and S.W. Lamberts (1999) Neuropeptides and their receptors in the immune system. Ann. Med. 31(Suppl. 2), 15-22.
271. J.A. Vilensky and J.A. Cook (1998) Neurogenic acceleration of osteoarthritis. Curr. Opin. Rheumatol. 10 251-255.
272. I. Villa, A. Rubinacci, F. Ravasi, A.F. Ferrara and E. Guidobono (1997) Effects of amylin human osteoblast-like cells. Peptides 18 537-540.
273. J.K. Voice, G. Dorsam, R.C. Chan, C. Grinninger, Y. Kong and E.J. Goetzl (2002) Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul. Pept. 109 199-208.
274. M.C. Walsh, N. Kim, Y. Kadono, J. Rho, S.Y. Lee, J. Lorenzo and Y. Choi (2006) Osteoimmunology: Interplay between the immune system and bone metabolism. Ann. Rev. Immunol. 24 33-63.
275. S.J. Warden, A.G. Robling, M.S. Sanders, M.M. Bliziotes and C.H. Turner (2005) Inhibition of serotonin (5-hydroxytryptamine) transporter reduced bone accrual during growth. Endocrinology 146 685-693.
276. S.J. Warden, M.M. Bliziotes, K.M. Wiren, A.J. Eshleman and C.H. Turner (2005) Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol. Cell Endocrinol. 242 1-9.
277. C. Wedemeyer, C. Neuerburg, A. Pfeiffer, A. Heckelei, F. von Knoch, G. Hilken, J. Brankamp, F. Henschke, M. von Knoch, F. Loer and G. Saxler (2007) Polyethylene particle-induced bone resorption in substance P deficient mice. Calcif. Tissue Int. 80 268-274.
278. I. Westbroek, A. van der Plas, K.E. de Rooij, J. Klein-Nulend and P.J. Nijweide (2001) Expression of serotonin receptors in bone. J. Biol. Chem. 276 28961-28968.
279. E. Wilmet, A.A. Ismail, A. Heilporn, D. Welraeds and P. Bergmann (1995) Longitudinal study of the bone mineral content and of soft tissue composition after spinal cord section. Paraplegia 33 674-677.
280. W. Windischhofer and H.J. Leis (1997) [3H]Bradykinin receptor-binding, receptor-recycling, receptor-internalization of the B2 bradykinin receptor in the murine osteoblast-like cell line MC3T3-E1. J. Bone Miner. Res. 12 1615-1625.
281. I. Yamamoto, N. Kitamura, J. Aoki, C. Shigeno, M. Hino, K. Asonuma, K. Torizaka, N. Fujii, A. Otaka and H. Yajima (1986) Human calcitonin gene-related peptide possesses weak inhibitory potency of bone resorption in vitro. Calcif. Tissue Int. 38 339-341.
282. J.I. Yamamura, Y. Takada, M. Goto, M. Kumegawa and S. Aoe (2000) Bovine milk kininogen fragment 1.2 promotes the proliferation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 269 628-632.
283. F. Yanaga, M. Hirata and T. Koga (1991) Evidence for coupling of bradykinin receptors to a guanine-nucleotide binding protein to stimulate arachidonate liberation in the osteoblast-like cell line MC3T3-E1. Biochim. Biophys. Acta 1094 139-146.
284. S. Yasunaga, H. Yonemochi, T. Saikawa and T. Sakata (2000) Bradykinin regulates captopril-induced upregulation of beta-adrenergic receptor in cultured neonatal rat cardiomyocytes. J. Mol. Cell Cardiol. 32 153-159.
285. T. Yucel-Lindberg, U.H. Lerner and T. Modéer (1995) Effects and interactions of tumour necrosis factor a and bradykinin on inter-leukin-1 production in gingival fibroblasts. J. Periodont. Res. 30 186-191.
286. M. Zaidi, T.J. Chambers, R.E. Gaines Das, H.R. Morris and I. Macln-tyre (1987) A direct action of human calcitonin gene-related peptide on isolated osteoclasts. J. Endocrinol. 115 511-518.
287. M. Zaidi, K. Fuller, P.J.R. Bevis, R.E. GainesDas, T.J. Chambers and I. MacIntyre (1987) Calcitonin gene-related peptide inhibits osteoclastic bone resorption: A comparative study. Calcif. Tissue Int. 40 149-154.
288. M. Zaidi, H.K. Datta, P.J. Bevis, S.J. Wimalawansa and I. Maclntyre (1990) Amylin-amide: A new bone-conserving peptide from the pancreas. Exp. Physiol. 75 529-536.